CVE-2026-73316XenForo < 2.3.13 Payment Replay via PayPal REST Payment Provider
Updated under an hour ago ()
Does this affect you?
It affects XenForo. Add what you run to find out whether that includes you.
No exploitation reported and no EPSS estimate yet.
Do this next
Free account, 1 product
XenForo before 2.3.13 contains a payment replay vulnerability in the PayPal REST payment provider that allows attackers to process the same webhook payload multiple times by exploiting a missing duplicate transaction ID check. Attackers can replay a valid webhook payload to trigger duplicate payment events, resulting in repeated subscription activations and unauthorized account upgrades.
- CVSS
- 7.5 HIGH (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:N
- Weakness (CWE)
- CWE-345
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- Not loaded for this CVE
- Assigned by
- VulnCheck
- NVD analysis
- Analyzed
- Record last updated
- Oct 1, 2026
- First seen by InfoSec Signals
- Oct 9, 2026
Affected products
XenForo XenForo xenforo:xenforo (from the name) | before 2.3.13 | CNA record |
xenforo xenforo xenforo:xenforo | before 2.3.13 | NVD |
References
- https://xenforo.com/community/threads/security-fixes-released-for-all-xenforo-and-media-gallery-versions-2-2-0-2-3-12.239856/vendor-advisory, patch, release-notes
- https://xenforo.com/community/threads/xenforo-2-3-13-and-add-ons-released-includes-security-fixes.239857/release-notes
- https://bombobombone.github.io/posts/cve-2026-73316/technical-description, exploit, third-party-advisory
- https://github.com/BomboBombone/CVE-2026-73316exploit, third-party-advisory
- https://www.vulncheck.com/advisories/xenforo-payment-replay-via-paypal-rest-payment-providerthird-party-advisory
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.